Jean Jacques Bienaime Purchases 1,000 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Jean Jacques Bienaime bought 1,000 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was purchased at an average cost of $21.55 per share, for a total transaction of $21,550.00. Following the transaction, the director owned 38,415 shares of the company’s stock, valued at $827,843.25. This trade represents a 2.67% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immunome Stock Down 3.0%

IMNM opened at $20.36 on Friday. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $27.65. The business has a fifty day simple moving average of $22.73 and a 200-day simple moving average of $18.06. The firm has a market cap of $2.30 billion, a P/E ratio of -8.41 and a beta of 2.12.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. Sell-side analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current year.

Institutional Investors Weigh In On Immunome

Hedge funds have recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. boosted its stake in shares of Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares during the period. Invesco Ltd. increased its stake in shares of Immunome by 382.1% during the fourth quarter. Invesco Ltd. now owns 270,065 shares of the company’s stock worth $5,801,000 after buying an additional 214,049 shares during the period. Virtus Investment Advisers LLC increased its stake in shares of Immunome by 16.9% during the fourth quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock worth $292,000 after buying an additional 1,970 shares during the period. Wellington Management Group LLP raised its holdings in Immunome by 267.8% in the fourth quarter. Wellington Management Group LLP now owns 934,463 shares of the company’s stock valued at $20,072,000 after acquiring an additional 680,395 shares in the last quarter. Finally, SummitTX Capital L.P. acquired a new stake in Immunome in the fourth quarter valued at approximately $2,741,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on IMNM shares. Craig Hallum boosted their price target on shares of Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Wedbush reaffirmed an “outperform” rating and set a $31.00 target price on shares of Immunome in a research note on Thursday, January 15th. Leerink Partners set a $40.00 target price on shares of Immunome in a report on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Thursday, January 22nd. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunome has an average rating of “Moderate Buy” and an average target price of $33.45.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.